Source comparison
Sermorelin vs Direct Testosterone Therapy: Mechanism Comparison
Primary Mechanism Stimulates endogenous GH release → modulates HPG axis indirectly via IGF-1 Directly replaces or supplements circulating testosterone Sermorelin is a signaling molecule; testosterone is hormone replacement Effect on Endogenous Production Prese
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Stimulates endogenous GH release → modulates HPG axis indirectly via IGF-1
- Directly replaces or supplements circulating testosterone
- Sermorelin is a signaling molecule; testosterone is hormone replacement
- Effect on Endogenous Production
- Preserves or enhances natural testosterone synthesis (if pathway is intact)
- Suppresses endogenous production via negative feedback on LH/FSH
- Sermorelin maintains HPTA function; TRT shuts it down
- Time to Measurable Effect
- 8–12 weeks for testosterone changes (if they occur)
- 2–4 weeks for symptom relief and serum level increase
- Sermorelin's effect is slower and conditional
- Magnitude of Testosterone Increase
- 10–18% in responsive populations (conditional on baseline GH/IGF-1 status)
- Can raise testosterone to supraphysiological levels (dose-dependent)
- TRT produces larger, more predictable increases
- Populations Most Responsive
- Men with age-related GH decline, metabolic syndrome, concurrent low IGF-1 and low testosterone
- Men with primary or secondary hypogonadism regardless of GH status
- Sermorelin works in a narrower subset
- Regulatory Status
- Prescription peptide; classified as a drug under FDA jurisdiction
- Schedule III controlled substance (DEA)
- Both require prescribing oversight. Sermorelin is not OTC